Literature DB >> 23602827

Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes.

David W C Beasley1, Merribeth Morin, Ashley R Lamb, Edward Hayman, Douglas M Watts, Cynthia K Lee, Dennis W Trent, Thomas P Monath.   

Abstract

Serial passaging of yellow fever virus 17D in Vero cells was employed to derive seed material for a novel inactivated vaccine, XRX-001. Two independent passaging series identified a novel lysine to arginine mutation at amino acid 160 of the envelope protein, a surface-exposed residue in structural domain I. A third passage series resulted in an isoleucine to methionine mutation at residue 113 of the NS4B protein, a central membrane spanning region of the protein which has previously been associated with Vero cell adaptation of other mosquito-borne flaviviruses. These studies confirm that flavivirus adaptation to growth in Vero cells can be mediated by structural or non-structural protein mutations.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Vaccine; Vero cells; Yellow fever virus

Mesh:

Substances:

Year:  2013        PMID: 23602827     DOI: 10.1016/j.virusres.2013.04.003

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  5 in total

1.  Predicting Zika virus structural biology: Challenges and opportunities for intervention.

Authors:  Bryan D Cox; Richard A Stanton; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2016-06-13

2.  Phenotypic and Genetic Variability of Isolates of ZIKV-2016 in Brazil.

Authors:  Lidiane Menezes Souza Raphael; Iasmim Silva de Mello; Mariela Martínez Gómez; Ieda Pereira Ribeiro; Nathália Dias Furtado; Noemia Santana Lima; Alexandre Araújo Cunha Dos Santos; Déberli Ruiz Fernandes; Stephanie Oliveira Diaz da Cruz; Luana Santana Damasceno; Patrícia Brasil; Myrna Cristina Bonaldo
Journal:  Microorganisms       Date:  2022-04-21

Review 3.  Current status and future prospects of yellow fever vaccines.

Authors:  Andrew S Beck; Alan D T Barrett
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

Review 4.  Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention.

Authors:  Joanna Zmurko; Johan Neyts; Kai Dallmeier
Journal:  Rev Med Virol       Date:  2015-04-01       Impact factor: 6.989

Review 5.  Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?

Authors:  Kay M Tomashek; Mark Challberg; Seema U Nayak; Helen F Schiltz
Journal:  Vaccines (Basel)       Date:  2019-11-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.